Loading...
XHKG
1652
Market cap32mUSD
May 30, Last price  
0.34HKD
1D
-1.45%
1Q
7.94%
IPO
-85.65%
Name

Fusen Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
0.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-1.62%
Rev. gr., 5y
-4.36%
Revenues
326m
-42.36%
368,634,000441,988,000452,580,000462,061,000407,388,000486,854,000385,664,000491,757,000565,608,000326,029,000
Net income
-189m
L+420.39%
44,879,00095,073,00096,820,000101,882,00053,434,00070,131,00016,645,000-34,654,000-36,277,000-188,783,000
CFO
0k
P
69,804,000172,345,000133,206,00062,818,00020,390,000153,207,00047,766,000110,490,000-73,334,0000
Dividend
Jun 07, 20220.0042 HKD/sh

Profile

Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
URL
http://www.fusenyy.com/
IPO date
Jul 11, 2018
Employees
1,121
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
326,029
-42.36%
565,608
15.02%
491,757
27.51%
Cost of revenue
410,935
561,523
470,754
Unusual Expense (Income)
NOPBT
(84,906)
4,085
21,003
NOPBT Margin
0.72%
4.27%
Operating Taxes
1,646
6,847
3,661
Tax Rate
167.61%
17.43%
NOPAT
(86,552)
(2,762)
17,342
Net income
(188,783)
420.39%
(36,277)
4.68%
(34,654)
-308.19%
Dividends
(6,959)
Dividend yield
0.64%
Proceeds from repurchase of equity
(15,988)
(10,073)
BB yield
1.55%
0.93%
Debt
Debt current
304,464
237,643
227,949
Long-term debt
80,284
108,331
2,971
Deferred revenue
10,231
11,323
Other long-term liabilities
18,124
Net debt
319,816
162,151
(70,900)
Cash flow
Cash from operating activities
(73,334)
110,490
CAPEX
(66,241)
(23,862)
Cash from investing activities
(108,318)
(13,131)
Cash from financing activities
88,503
(51,766)
FCF
(9,913)
(377,992)
82,303
Balance
Cash
21,056
34,849
128,106
Long term investments
43,876
148,974
173,714
Excess cash
48,631
155,543
277,232
Stockholders' equity
368,362
331,533
312,141
Invested Capital
721,549
761,029
543,537
ROIC
2.98%
ROCE
0.45%
2.55%
EV
Common stock shares outstanding
739,982
752,056
756,074
Price
1.37
-4.20%
1.43
15.32%
Market cap
1,030,317
-4.70%
1,081,186
13.19%
EV
1,191,176
1,009,012
EBITDA
(84,906)
39,883
55,164
EV/EBITDA
29.87
18.29
Interest
12,583
12,382
Interest/NOPBT
308.03%
58.95%